Introduction
Dose-intensified or high-dose chemotherapy may increase the remission rate and long-term survival of patients with various types of cancer. 1 Chemotherapeutic agents also damage highly proliferating and regenerating normal tissues. This applies in particular to the hematopoietic system, and hematologic side effects often severely limit the potential to apply dose-escalated therapy. Overexpression of genes conferring resistance to chemotherapeutic agents in the hematopoietic system represents a promising approach to circumvent this problem and may allow the application of chemotherapy with acceptable side effects. To this end, several drug resistance genes such as the multidrug-resistance-1 (MDR-1) gene, mutated dihydrofolate reductase (DHFR), and the human O 6 -methylguanine-DNAmethyltransferase (MGMT) gene have successfully been investigated (for reviews, see Moritz and Williams 2 and Flasshove et al 3 ). More recently, the cytidine deaminase (CDD) gene, which protects cells from cytotoxic deoxycytidine analogs such as cytarabine (1-b-D-arabinofuranosylcytosine) and gemcitabine (2 0 ,2 0 -difluorodeoxycytidine), has been introduced as a drug resistance gene with considerable clinical potential. For both drugs, myelosuppression represents a major and often doselimiting side effect. CDD deaminates cytosine nucleosides and their analogs such as cytarabine and gemcitabine, thus preventing the accumulation of their toxic intracellular triphosphate derivatives, which act as the active metabolites. 4, 5 Following cloning and sequencing of the human CDD cDNA, 6 the protective potential of CDD against cytarabine was demonstrated in fibroblasts and hematopoietic cell lines. [7] [8] [9] In addition, we and others have shown increased cytarabine resistance after retrovirally mediated transduction of primary murine hematopoietic cells. [10] [11] [12] More recently, increased gemcitabine and 5-aza-2 0 -deoxycytidine resistance after CDD gene transfer into murine cells 13, 14 and transfer of the CDD gene into primary murine bone marrow stromal cells, followed by in vitro enrichment of these cells by cytarabine application, have been described. 14 Successful treatment of lymphoma with a combination of methotrexate and cytarabine in NOD/SCID mice transplanted with drug-resistant bone marrow could also be demonstrated. 15 Thus far, data for the successful transduction of primary human hematopoietic cells with CDD are missing although human CD34 þ cells have low CDD enzymatic activity, 8 rendering them an excellent target cell population for this approach. Therefore, we have investigated CDD gene transfer into primary human hematopoietic cells, demonstrating that human progenitor cells can be retrovirally transduced, rendered significantly resistant to cytarabine and gemcitabine, and successfully selected in vitro.
Material and methods

Retroviral vectors
The retroviral vectors pSFb1-EGFP and pSF91-CDD-IRES-EGFP ( Figure 1a ) are based on the spleen focus-forming virus (SFFV)/ murine embryonic stem cell virus (MESV) hybrid backbones pSF91 16 and pSF1. 17 Construction of pSFb1-EGFP has previously been described. 18 To generate pSF91-CDD-IRES-EGFP, the CDD open reading frame plus Kozak sequence 19 was first PCR amplified using primers 5 0 : ggg aat tca aca tgg ccc aga agc gtc ctg; 3 0 : gga tcc tca ctg agt ctt ctg cag gtc ctc from another CDD-containing vector 8 and ligated into pCR s 2.1 (Invitrogen). After sequence verification (ALF, Pharmacia Biotech), the CDD cDNA was excised with EcoRI and BamHI and ligated into the retroviral vector pSF91-hOGG1-IRES-EGFP, 20 replacing the OGG1 EcoRI/BamHI fragment.
Producer cell line
Supernatants of FNX-Eco packaging cells 21 transfected with the vector constructs served to transduce PG13 packaging cells, 22 from which stable producer clones were established. In brief, DNA for transfections was prepared using Endofree Plasmid Kit (Qiagen), and 3 Â 10 6 FNX-Eco cells were plated per 10 cm tissue culture dish in IMDM (10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin (P/S); all Sigma). The next day, transfection was performed for 6 h with 10 mg of plasmid DNA and 30 mg of DAC30 transfection reagent (Eurogentec) before medium change and overnight incubation at 321C, 5% CO 2 . The supernatant was harvested 48 and 72 h after transfection, filtered (0.45 mm pore size; Sartorius), and stored at À801C. In all, 5 ml of each FNX-Eco supernatant was used to transduce PG13 cells grown to 80% confluency in 10 cm tissue culture dishes in the presence of 4 mg/ml polybrene (Sigma). After expansion, PG13 cells were sorted for EGFP expression (FACSVantage, Becton Dickinson) and cloned in 96-well plates at a density of 0.5 cells per 200 ml per well. High EGFPexpressing clones were identified by flow cytometry with EPICS XL (Coulter Electronics). For supernatant production, 5-7 Â 10 6 cells of each clone were cultivated in a 10 cm petri dish in IMDM (20% FCS, 2 mM L-glutamine, P/S) at 321C and 5% CO 2 , and the supernatant was harvested 48 and 72 h after plating, filtered, and stored at À801C.
Titer analysis of retroviral supernatant
Virus supernatants generated by individual producer clones were titrated on HT1080 cells and one clone for each vector titrating at 2 Â 10 4 infectious particles/ml was used for further experiments. Titration was performed as follows: 3 Â 10 4 cells of the human fibroblast cell line HT1080 were seeded in six-well plates and cultivated overnight. Cells were transduced for 4 h with 1 ml virus-containing supernatant used at different dilutions in the presence of 8 mg/ml polybrene. On day four, the transduced cells were analyzed by flow cytometry. The titer was calculated by multiplying the cell number present at the time of transduction with the percentage of EGFP þ cells and the dilution factor. Of note, infectious particles as measured by this HT1080-based assay reproducibly underestimate the actual number of infectious particles by 1.0-1.5 log (own observation when compared to titer assays using HeLa cells) as titers of 1-3 Â 10 4 infectious particles/ml measured by the HT1080 assay reproducibly transduce primitive human NOD/SCID repopulating cells.
Source, transduction, and sorting of CD34 þ umbilical cord blood cells
Umbilical cord blood cells and mobilized peripheral blood stem cells (PBSC) generated as described previously 23 Gene transfer of cytidine deaminase W Bardenheuer et al flow cytometry using FITC-coupled anti-CD34 antibodies (Becton Dickinson) was 81.272.1% (n ¼ 14). Thereafter, retroviral transduction of CD34 þ cells in the presence of fibronectin fragments was performed as described previously, 23 with minor modifications. In short, 0.5-1 Â 10 6 CD34 þ enriched cells were prestimulated for 24 h in the presence of 10 ng/ml rhIL-3, 20 ng/ ml rhIL-6 (both kindly provided by Novartis AG), and 20 ng/ml rhSCF (CellGenix), and thereafter transduced by incubation in 2 ml of viral supernatant in the presence of the same cytokines for four times over a period of 48 h. In some experiments, transduced CD34 þ cells were sorted for EGFP expression using a FACS sorter (FACS Vantage) prior to further analysis ( Figure 1b ).
Clonogenic progenitor assay
Clonogenic progenitor cells (CFU-C) were propagated using standard methylcellulose assay as described previously, 23, 24 with minor modifications: 1-2 Â 10 3 CD34 þ enriched cells (post-transduction) or 0.1-2.3 Â 10 4 cells (after in vitro selection) were incubated in 1 ml of IMDM/0.9% methylcellulose (Fluka) supplemented with 35% FCS, 10 ng/ml rhIL-3, 20 ng/ml rhIL6, 10 3 U/ml rhG-CSF (Amgen), 20 ng rhSCF, 6 U/ml rhEPO (Boehringer Mannheim), and 5 Â 10 À5 M 2-mercaptoethanol (Sigma). In all, 10-500 nM of cytarabine (Pharmacia & Upjohn) or 1-30 nM of gemcitabine (Lilly Deutschland), respectively, were added once to the cultures on day 0. Colonies (450 cells) were counted after 10-14 days as CFU-GM or BFU-E/CFU-Mix according to their morphology. Survival of CFU-C was calculated relative to the number of colonies in cultures without the drug.
In vitro selection of CDD-transduced cells in suspension culture
Following transduction, 2 Â 10 4 CD34 þ enriched cells were plated in six-well dishes in IMDM (20% FCS, 2 mM L-glutamine, P/S) with 10 ng/ml rhIL-3, 20 ng/ml rhIL-6, 20 ng/ml rhSCF, and 103 U/ml rhG-CSF. Cytarabine was added at concentrations of 0 nM (control), 30, 60, or 100 nM. After 4 days, the percentage of EGFP-expressing cells was measured by flow cytometry, and clonogenic assays were performed using increasing concentrations of cytarabine.
Statistics
IC 50 values for colony survival at individual drug concentrations were determined using linear interpolation between the concentrations above and below the IC 50 . All data are expressed as mean7standard error of the mean (s.e.m.). To test for significant differences between CDD-and control-transduced cells, Student's t-test for paired samples was applied, with a P-value o0.05 considered significant.
Results
Cytarabine resistance of CDD-transduced progenitor cells
In six experiments, cytarabine resistance of clonogenic progenitor cells transduced with SF91-CDD-IRES-EGFP or SFb1-EGFP was compared. Transduction efficiency was reproducible for both vectors, with 2872% for SF91-CDD-IRES-EGFP and 3072% for SFb1-EGFP, as measured by expression of the EGFP marker gene. However, as depicted in Figure 2a , the percentage of surviving colonies was increased for SF91-CDD-IRES-EGFPtransduced cells at all concentrations higher than 10 nM, and showed significant differences between the two groups over a range from 20 to 100 nM of cytarabine (Po0.05), whereas for 200-500 nM differences were not significant, due to high interexperimental variations. Differences tended to be larger for erythroid colonies (BFU-E/CFU-Mix), being significant at 20-100 nM (Figure 2c ), while for CFU-GM significant differences were observed at 60 and 200 nM only (Figure 2b ). The same pattern was reflected in IC 50 values (Table 1) , which on average increased 1.7-fold for total CFU-C, 1.9-fold for BFU-E/ CFU-Mix, but only 1.2-fold for CFU-GM.
In order to more stringently analyze the cytarabine resistance conferred by CDD gene transfer, five additional experiments were performed, two with cord blood-derived cells and three with PBSCs. In these experiments, transduced cells were sorted by flow cytometry for EGFP expression prior to analysis in clonogenic assays (EGFP-positive cells ranging from 69 to 95%). Results from these experiments are depicted in Table 2 , and confirm the significant differences of cytarabine resistance observed between SF91-CDD-IRES-EGFP-and SFb1-EGFPtransduced progenitor cells. Thus, IC 50 values of CDD-transduced total colonies on average were 2.6-or 3.3-fold higher for cord blood-or PBSC-derived cells, respectively, when compared to controls. This increase is substantially higher than the 1.7-fold increase observed for nonsorted cells (see Table 1 ). A similar increase in the protective effect was observed when myeloid-or red cell-containing colonies were analyzed separately. In contrast to cord blood cells for which protection in particular was observed for red cell-containing colonies, protection in the PBSC experiments was most prominent for myeloid colonies.
Gemcitabine resistance of CDD-transduced progenitor cells
Gemcitabine resistance of clonogenic cord blood-derived progenitor cells transduced with either SF91-CDD-IRES-EGFP or SFb1-EGFP was evaluated in four experiments with EGFP þ enriched cells. Gemcitabine concentrations ranged from 1 to 30 nM. The rate of EGFP þ cells was 22.073.1% for SF91-CDD-IRES-EGFP-and 31.874% for SFb1-EGFP-transduced cells before enrichment and 69-96%, respectively, after enrichment. For CDD-transduced cells, increased gemcitabine resistance of clonogenic progenitors was observed over a dose range from 3 to 30 nM. For total CFU-C, these differences reached significance for 8-10 nM gemcitabine (Figure 3a) . However, in contrast to the data observed with cytarabine, protection of cord bloodderived cells from gemcitabine toxicity was more pronounced in myeloid than in erythroid cells. While for CFU-GM significant protection of CDD-transduced cells was observed for gemcitabine doses ranging from 3 to 15 nM, in BFU-E/CFU-Mix significant differences were observed for 8 nM only (Figure 3b and c, respectively). Protection was also evident calculating the IC 50 values. Here, on average, an 1.8-fold increase with CDD transduction was observed for total CFU-C, with a 3.0-fold increase for CFU-GM, but only a 1.4-fold increase for BFU-E/ CFU-Mix (Table 3) .
Interestingly, in our experiments with sorted cells, an inhibitory effect of SF91-CDD-IRES-EGFP transduction on myeloid colony formation was noted, and in the absence of cytotoxic drugs 37.275.2% less CFU-GM as compared to SFb1-EGFP transduction was observed (n ¼ 5; P ¼ 0.007). No significant differences were observed for erythroid colonies.
In vitro selection of CDD-transduced progenitor cells
To assess the in vitro selectability of CDD-transduced progenitor cells, retrovirally transduced cells in suspension cultures were exposed to 0, 30, 60, or 100 nM cytarabine for 4 days. Thereafter, EGFP expression in the remaining cells as well as cytarabine resistance of clonogenic progenitors were assessed and compared with preselection data. In comparison to control cultures set up without cytarabine, substantial enrichment of EGFP þ cells was detected in cytarabine-exposed CDD-transduced cells. This enrichment was highly significant (Po0.001) for all cytarabine concentrations tested, with the highest selection rate observed at a concentration of 60 nM cytarabine. Here, an increase in percentage of EGFP þ cells from 25.274.6 to 38.975.7% for SF91-CDD-IRES-EGFP was observed, while no significant increase was observed for SFb1-EGFP-transduced cells (n ¼ 10). A moderate but significant increase in the percentage of SFb1-EGFP cells also was detected when non-CDD-transduced control cells cultured without cytarabine were Cytarabine resistance of CDD-transduced CFU-C. Survival of CFU-C (a), CFU-GM (b) and BFU-E/CFU-Mix (c) following transduction of CD34 þ enriched umbilical cord blood cells with SFb1-EGFP (&) and SF91-CDD-IRES-EGFP (') retroviral vectors is given as mean7s.e.m. (n ¼ 6). CFU-C: colony-forming unit cells; CFU-GM: colony-forming units-granulocytes and macrophages; BFU-E/ CFU-Mix: burst-forming units-erythrocytes plus colony-forming units containing myeloid and erythroid progenitors.
n/nn Indicates significant differences (Po0.05/Po0.01) by Student's t-test. Functional cytarabine resistance of CFU-C after in vitro selection with 0 or 60 nM cytarabine is shown in Figure 4 . A selective effect of cytarabine exposure on resistance of SF91-CDD-IRES-EGFP-transduced CFU-C was observed after selection with 60 nM cytarabine (Figure 4a and c) . This effect was most pronounced at higher doses of cytarabine and reached statistical significance for progenitors resistant to 300 nM. Notably, 6.471.3 vs 2.570.9% progenitors resistant to 300 nM, and 3.771.4 vs 0.370.3% progenitors resistant to 500 nM cytarabine were detected when cells were selected in 60 nM in comparison to 0 nM cytarabine (n ¼ 4). A similar degree of increase in cytarabine resistance was observed when CFU-GM alone instead of total CFU-C was analyzed (Figure 4b  and d) .
This increase in functional Ara-C resistance went along with increased transgene expression, as measured by the mean fluorescence intensity (MFI) of the EGFP marker gene. Following 4 days of culture in the presence of 30, 60, or 100 nM Ara-C, moderately, though significantly, increased MFI levels of 34.774.1 (P ¼ 0.03), 36.174.8 (P ¼ 0.009), or 38.875.3 (P ¼ 0.026), respectively, were observed, when compared to control cells cultured without Ara-C (29.973.0; n ¼ 11; all MFI in rel. units).
Discussion
CDD deaminates deoxycytidine analog-type cytotoxic drugs such as cytarabine, gemcitabine, and 5-aza-2 0 -deoxycytidine, thereby preventing the intracellular accumulation of their active metabolites. Consequently, CDD has been considered a potential drug resistance gene and this capacity has been demonstrated in cell lines and in the murine hematopoietic system. [7] [8] [9] [10] [11] [12] To our knowledge, our study for the first time transfers these data to primary human hematopoietic cells. The degree of resistance to cytarabine or gemcitabine which we observed in human hematopoietic cells was comparable to that already described in hematopoetic cell lines or primary murine hematopoietic cells. Here, in general, resistance to cytarabine doses ranging from 10 to 500 nM 11, 25 and gemcitabine doses ranging from 1 to 10 nM 9 has been reported, with the only exception of early work from Momparler et al 12 reporting resistance of CFU-C to cytarabine doses of up to 50 mM. However, also this group later described resistance in the aforementioned dose range only. 25 These similarities between murine and human data were expected, as for both human and murine CD34 þ cells low CDD enzyme activity has been shown 8 and in both species the hematopoietic system represents a critical target organ for cytarabine-as well as gemcitabineinduced toxicity. 25, 26 From a clinical perspective, these data appear highly relevant. Cytarabine is the most effective single agent in the treatment of acute myeloid leukemia, and additionally shows considerable activity in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Gemcitabine is effective in lung, pancreatic, breast, ovarian, and other carcinomas, as well as lymphomas, and due to its favorable toxicity profile has gained widespread therapeutic acceptance in these disease entities. Therapeutically, cytarabine is most frequently applied at conventional doses of 100-200 mg/m 2 for a 5-7-day continuous infusion, resulting in steady-state plasma concentrations of 100-1200 nM. Given that -within certain limits -the product of drug concentration and exposure time is the most reliable parameter to predict cytarabine toxicity, and taking into account that in our experimental system cells were exposed to up to 500 nM cytarabine for 10-14 days, our data strongly suggest that protection of hematopoietic cells from conventional doses of cytarabine should be possible. Whether protection can be achieved also from high-dose (3 g/m 2 ) cytarabine application remains to be seen. With gemcitabine, the situation is more controversial. This drug is usually given as a 30-min infusion at a dose of 1200 mg/m 2 , resulting in peak plasma levels of 25-54 mM.
27 This is clearly higher than the 3-15 nM range in which resistance was observed in our studies. On the other hand, conventional dose gemcitabine application is clearly not myeloablative, indicating that this dose is survived by a substantial proportion of progenitor cells. Thus, our data showing significant protection of CFU-C close to 10-15 nM, which is the totally inhibitory concentration in our experimental setting, argue for a potential clinical benefit of CDD gene transfer. For both drugs, however, further investigations in relevant in vivo models will be required for a definite answer.
A potential obstacle to the clinical application of CDD gene transfer is the moderate, though significant, inhibitory effect on myeloid colony formation observed in our experiments following transduction with pSF91-CDD-IRES-EGFP. This may indicate a toxic effect of CDD expression in particular on myelopoiesis. Growth inhibition of human and murine CFU-GM following CDD exposure has been described previously, though only in the context of supraphysiological thymidine concentrations. 28 Toxicity of the retrovirus-containing supernatant for myeloid progenitor cells is another potential explanation for the inhibitory effect. Meanwhile, we have demonstrated that this, indeed, is at least part of the problem. Here, high CDD protein levels of producer cell lines, which have been selected by cytarabine exposure and may secrete the protein into the supernatant, are more than likely an issue, but this has not been studied in detail yet. More importantly, however, experiments in a murine bone marrow transplant/gene therapy model as well as preliminary data from NOD/SCID xenotransplants have failed to reproduce this effect, and strongly indicate that myelotoxicity does not represent a substantial problem in the in vivo situation (manuscript in preparation).
With IC 50 ratios of 1.2-3.6 between CDD-transduced and nontransduced cells, the degree of resistance conferred by CDD expression in CD34 þ cells appears moderate in comparison to the protection observed with other drug resistance genes such as MGMT, DHFR, or MDR-1. Here, increases in the order of 1.3-6-fold for MGMT, 29 but also up to 40-fold for mutant DHFR 23, 30 have been described. One obvious way to increase resistance Gene transfer of cytidine deaminase W Bardenheuer et al levels would be better transgene expression. While vectors employing the SFFV/MESV promotor/enhancer activity have given excellent results with other therapeutic and marker genes in our as well as other investigators' hands, 11, 17, 18, 23, 29, [31] [32] [33] retroviral expression of transgenes from a specific retroviral construct has repeatedly been demonstrated to be transgene specific. Thus, the degree of hematoprotection achieved by CDD expression might be increased not only by the use of new and optimized retroviral vector backbones but also by using other vector systems such as lenti-or foamyvirus-based constructs. [34] [35] [36] Another promising approach to utilize CDD gene transfer clinically may be the combination with other drug resistance genes. Retroviral constructs allowing the simultaneous expression of CDD and mutant DHFR in hematopoietic cells have been described. 10 Given the high therapeutic efficiency of cytarabine in lymphoma and AML, the MDR-1 gene protecting cells against anthracyclines, another highly effective class of drugs in these diseases, represents a logical combination partner. Also, combinations with MGMT may be applicable to the treatment of lymphomas. Along a similar line, successful treatment of lymphoma recently has been reported in a mouse model utilizing CDD-and mutant DHFR-transduced bone marrow to protect the hematopoietic system from the combined application of methotrexate and cytarabine. 15 In our studies, moderate, though significant, in vitro selection of CDD-transduced cells following exposure to cytarabine is demonstrated. This is in contrast to previous experiments performed with primary mononuclear murine bone marrow cells in which in vitro selection was prevented by the release of large amounts of CDD from CDD-transduced cells. 37 Therefore, another attractive application of CDD gene transfer may be the enrichment of genetically modified cells for gene therapy of monogenetic diseases. Here, selection strategies have been advocated for diseases caused predominantly by malfunction of hematopoietic cells in which the introduced therapeutic transgene does not confer a selective growth advantage to the transduced cells such as chronic granulomatous or Gaucher's disease. 38 In this context, CDD appears as a particularly suitable selection marker, because low-and intermediate-dose cytarabine -in contrast to other cytotoxic agents associated with drug resistance genes -can be applied without significant nonhematological toxicity.
In summary, the data presented here for the first time show protection of human hematopoietic cells against drugs inactivated by CDD following overexpression of this enzyme. Before clinical application of CDD gene transfer, a number of issues such as the analysis of possible toxicity, the confirmation of our results in relevant in vivo models, or in the case of leukemic disease the risk of inadvertent transduction of tumor cells certainly need to be addressed. If these problems can be overcome, however, CDD overexpression may represent an attractive approach to achieve hematoprotection for clinically highly relevant drugs.
